Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Onconova Therapeutics, Ir	nc.								
Form 4 April 20, 2015									
								PPROVAL	
Washington, D.C. 20549							N OMB Number:	3235-0287 January 31,	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer subject to SECURITIES STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type Responses)									
1. Name and Address of Report Guerin Mark Patrick	2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ONTX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) C/O ONCONOVA THERAPEUTICS, INC., PHEASANT RUN	(Month/Day	3. Date of Earliest Transaction (Month/Day/Year) 04/16/2015				Director10% Owner Officer (give titleOther (specify below)below) Chief Accounting Officer			
(Street)	Filed(Month/Day/Yea				1	y One Reporting P	int/Group Filing(Check one Reporting Person fore than One Reporting		
NEWTOWN, PA 18940						Person	More than one is	aporting	
(City) (State)	(Zip)	Table I	- Non-D	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned	
1.Title of Security2. Transaction D (Month/Day/Yea (Instr. 3)		Date, if Tra Co ay/Year) (In	ansaction ode nstr. 8)	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Report on a separate	line for each c	lass of securiti	ies benef	icially own	ned directly	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e any Code Securities (Month/Day/Year) (Instr. 8) Acquired (A		A)	6. Date Exerc Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code V	(A)	` '	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right ot purchase)	\$ 2.32	04/16/2015		А	15,000		<u>(1)</u>	04/16/2025	Common Stock	15,000
Reporting Owners										
Reporting Owner Name / Address			Relation			lips				
		Director	10% Owner	Officer			Other			
Guerin Mark Patrick C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940 Signatures			NC.	Chief Accounting Officer						
Jighat	uics									

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Mark Guerin 04/20/2015

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options vest over four years in 48 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.